Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Lexaria Bioscience (LEXX) over the last 12 years, with Q3 2025 value amounting to 1543.16%.

  • Lexaria Bioscience's EBITDA Margin rose 10553400.0% to 1543.16% in Q3 2025 from the same period last year, while for Nov 2025 it was 2077.82%, marking a year-over-year decrease of 5993100.0%. This contributed to the annual value of 1693.15% for FY2025, which is 4406400.0% down from last year.
  • According to the latest figures from Q3 2025, Lexaria Bioscience's EBITDA Margin is 1543.16%, which was up 10553400.0% from 2156.28% recorded in Q2 2025.
  • Lexaria Bioscience's 5-year EBITDA Margin high stood at 465.2% for Q1 2024, and its period low was 14434.31% during Q4 2021.
  • For the 5-year period, Lexaria Bioscience's EBITDA Margin averaged around 2898.61%, with its median value being 1959.59% (2022).
  • As far as peak fluctuations go, Lexaria Bioscience's EBITDA Margin tumbled by -142025600bps in 2021, and later soared by 126376700bps in 2022.
  • Lexaria Bioscience's EBITDA Margin (Quarter) stood at 14434.31% in 2021, then surged by 88bps to 1796.64% in 2022, then soared by 57bps to 776.68% in 2023, then plummeted by -89bps to 1471.74% in 2024, then decreased by -5bps to 1543.16% in 2025.
  • Its EBITDA Margin stands at 1543.16% for Q3 2025, versus 2156.28% for Q2 2025 and 1614.06% for Q1 2025.